Skip to main content

Kevin Winthrop

Kevin L. Winthrop is Professor of Infectious Diseases and Ophthalmology at the School of Medicine and a Professor of Public Health at the OHSU-PSU School of Public Health at Oregon Health & Science University (OHSU) in Portland, Oregon, USA.

Dr Winthrop received his undergraduate degree in biology from Yale University, New Haven, Connecticut, USA and his MD from OHSU. He completed his internal medicine residency training at Legacy Emanuel Hospital, Portland. He then completed an infectious disease epidemiology fellowship at the US Centers for Disease Control and Prevention (CDC). In 2003, Dr Winthrop was conferred a Master in Public Health from the University of California, Berkley, California, USA. In 2006, Dr Winthrop returned to OHSU as Assistant Professor before progressing to his current appointment in 2012.

A former infectious disease epidemiologist in the Division of Tuberculosis Elimination at the CDC, Dr Winthrop has co-authored over 200 publications, many regarding the epidemiologic and clinical aspects of opportunistic infections associated with immune-mediated inflammatory diseases, particularly those related to biologic immunosuppressive therapies.

As a primary or senior investigator in many clinical or epidemiologic studies in these fields, he has collaborated closely with the rheumatology community in the evaluation and prevention of opportunistic infections in that setting. In addition, he is also a member of the graduate faculty at OHSU where he mentors public health students, medical students, and physicians in post-graduate training.

print
PRINT

Latest contributions from Kevin Winthrop

Richard Conway and Kevin Winthrop

05-08-2022 | JAK inhibitors | Video | Article

Have the ORAL Surveillance results changed rheumatology practice?

Following publication of the ORAL Surveillance trial, Richard Conway and Kevin Winthrop discuss the impact of the findings on JAK inhibitor prescribing, how regulatory recommendations compare in Europe and the USA, and whether the risks seen with tofacitinib represent a class effect.

coronavirus Covid-19 virus in a laboratory

24-03-2020 | Infection | Podcast | Article

COVID-19 in people with rheumatic diseases

Kevin Winthrop, from Oregon Health & Science University in Portland, USA, discusses why patients with rheumatic diseases may be vulnerable to COVID-19 and how different treatments may affect the risk for infection and prognosis of the disease (10:31).